MARKET

TRDA

TRDA

Entrada Therapeutics, Inc.
NASDAQ
7.97
-0.73
-8.39%
After Hours: 7.97 0 0.00% 16:20 05/14 EDT
OPEN
8.70
PREV CLOSE
8.70
HIGH
8.75
LOW
7.95
VOLUME
150.49K
TURNOVER
--
52 WEEK HIGH
21.79
52 WEEK LOW
7.10
MARKET CAP
302.49M
P/E (TTM)
9.86
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at TRDA last week (0505-0509)?
Weekly Report · 2d ago
Entrada Therapeutics price target lowered to $21 from $23 at Roth Capital
TipRanks · 3d ago
Analysts Have Conflicting Sentiments on These Healthcare Companies: Entrada Therapeutics Inc (TRDA) and Qiagen (QGEN)
TipRanks · 3d ago
Entrada Therapeutics: Strategic Advancements in DMD Pipeline Drive Buy Rating
TipRanks · 6d ago
Analysts Offer Insights on Healthcare Companies: Entrada Therapeutics Inc (TRDA), Galmed Pharmaceuticals (GLMD) and Xilio Therapeutics (XLO)
TipRanks · 6d ago
Entrada Therapeutics GAAP EPS of -$0.42 beats by $0.37, collaboration revenue of $20.56M
Seeking Alpha · 6d ago
Entrada Therapeutics, Inc. Reports Quarterly Results for the Period Ended March 31, 2025
Press release · 6d ago
Entrada Therapeutics, Inc. (TRDA) Reports Q1 Loss, Tops Revenue Estimates
NASDAQ · 6d ago
More
About TRDA
Entrada Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is engaged in establishing a class of medicines, which engages intracellular targets. Its Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the delivery of a range of therapeutics into a variety of organs and tissues, resulting in an improved therapeutic index. The Company is advancing a robust development portfolio of RNA-, antibody- and enzyme-based programs for the potential treatment of neuromuscular, ocular, metabolic and immunological diseases, among others. It is engaged in preclinical lead optimization efforts in both neuromuscular and non-neuromuscular disease and discovery efforts to advance platform applications. Its lead oligonucleotide programs are in development for the potential treatment of people living with Duchenne who are exon 44, 45, 50 and 51 skipping amenable. It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.

Webull offers Entrada Therapeutics Inc stock information, including NASDAQ: TRDA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TRDA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading TRDA stock methods without spending real money on the virtual paper trading platform.